Australian anti-aging industry exploits regulatory gaps, risks consumer safety

Australia's burgeoning anti-aging industry, promising to reverse the clock on aging, is exploiting significant gaps in health regulation, exposing consumers to potential risks. Around 100 operators have emerged across the country, offering services like IV drips, red light therapy, and hyperbaric chambers, all marketed to keep individuals young, beautiful, strong, and energetic.

Treatments such as NAD+ infusions, promoted to boost energy and longevity, are offered despite limited human evidence. Similarly, peptides, short chains of amino acids, are being widely marketed for cosmetic and vitality benefits. While some peptides like insulin are mainstream, those used in the anti-aging sector are often unproven and unapproved, with many sourced from overseas black markets or prescribed by Australian wellness clinics.

To investigate the ease of obtaining these treatments, a health reporter booked a "peptide therapy" consultation. After completing a lengthy questionnaire and undergoing blood tests, she was offered a telehealth appointment. The clinic required an informed consent form, which advised of alternatives like lifestyle changes or no treatment, advice that seemed disconnected as the doctor had not yet been consulted. The reporter spent approximately $400 on tests, a GP visit, and the consultation fee.

During the telephone consultation, the doctor reviewed the reporter's medical history. When asked about the reason for the appointment, the reporter described common concerns of middle-aged women, including feeling older and less energetic. The article highlights how the marketing of these anti-aging treatments often outpaces scientific evidence, leaving consumers vulnerable to potentially ineffective or unsafe therapies.